Current clinical trial results indicate that dMMR-MSI-H CRC is relatively sensitive to treatment with immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 inhibitors, compared to pMMR-MSI-L CRC [4,5]. The gene discussed is PDCD1; the disease is colorectal carcinoma.